Wednesday, February 3, 2021 (A: Cannabis in Pregnancy & Breast Milk)
Wednesday, February 10, 2021 (B: CBD, Pregnancy, & Outcomes)
2 webinars x 120 minutes including a Q&A
Includes (for each webinar):
• A certificate of completion
• The live webinar event if registering prior to commencement
• The on-demand recording to watch at your convenience
• A handout in PDF format for viewing or self-printing
Cannabis is currently one of the most commonly used drugs during pregnancy; use in Canada is estimated to be between 35 and 60% of women continue to use cannabis throughout their pregnancy. As new research continues to throw light on the effects of cannabis on the mother, the fetus, breast milk and later, the impact on children who were exposed pre-natally to cannabis, nurse must be aware of the facts in order to care and counsel mothers at each stage of the perinatal experience.
Objectives for “A: Cannabis in Pregnancy & Breast Milk”
• Describe various ingestion routes of cannabis and transference to the fetus.
• Relate professional organization recommendations regarding cannabis in pregnancy and human milk
• Describe potential fetal brain changes after exposure to cannabis.
• Differentiate hyperemesis gravidarum and cannabinoid hyperemesis.
• Discuss potential birth and neonatal outcomes of prenatal ingestion of cannabis.
• Discuss potential outcomes for older children exposed prenatally to cannabis.
• Discover resources available for pregnant and lactating women considering cannabis use.
Objectives for “B: CBD, Pregnancy, & Outcomes”
• Differentiate various components of the endocannabinoid system
• Relate regulations regarding CBD manufacture
• Describe various ingestion routes of CBD and transference to the fetus
• Relate recommendations regarding CBD in pregnancy and human milk
• Discuss potential birth and neonatal outcomes of prenatal ingestion of CBD.
• Discuss potential outcomes for older children exposed prenatally to CBD.
Who Should Attend?:
• Obstetrical Nurses; L&D, Midwives, Ante and Postpartum; Fetal Assessment Nurses, Lactation Consultants
• Neonatal Nurses: Level 1, 2, & 3 Nursery Staff; Neonatal Nurse Practitioners
• Childbirth, Obstetrical and Neonatal Educators; Managers
• Women’s Health Practitioners; Intimate Partner Violence Counsellors; Selected Gyne & Public Health Nurses
• Social Workers, Substance Use Counsellors, Sexual Health Counsellors
Maureen Shogan, MN, RNC
Maureen is currently the Clinical Director for a National Institute on Drug Abuse (NIDA) Phase 2 project on developing Neonatal Abstinence Curriculum for mobile devices. She has had varied nursing experiences as a Neonatal Clinical Nurse Specialist, Nurse manager, transport nurse and staff nurse in a 46 bed Level III NICU and 26 bed Mother Baby unit in Spokane, WA. She was also the liaison between the NICU and inpatient Chemical Dependency Unit for pregnant and parenting women with Substance Use Disorder. She is adjunct nursing faculty at Washington State University. She is an active member of the Washington State Perinatal Collaborative as well as the WA state Pregnant and Parenting Opioid Workgroup. As a member of the Spokane Regional Health District Birth Outcomes Task Force, she was instrumental in the development of “Weed to Know: Marijuana in Pregnancy and Breast Feeding” as well as “Newborn Withdrawal” parent education materials.
She has written numerous clinical papers and has given dynamic and memorable daylong workshops throughout the US and Canada as an invited speaker at national and regional conferences. She is passionate about professional nursing and multidisciplinary collegial relationships. She is both a Washington State Cougar (MN) and Gonzaga University (BSN) Bulldog. Her goal is to visit all Canadian Provinces/ Territories. 9 down, 4 to go.